India, Nov. 11 -- Wednesday, Kura Oncology, Inc. (KURA) reported third-quarter 2026 financial results, with KOMZIFTI net product revenue increasing 53% sequentially to $13.9 million. The company also highlighted progress in its acute myeloid leukemia (AML) programs and its investigational drug candidate darlifarnib for solid tumors.
Company Profile
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its portfolio includes KOMZIFTI (ziftomenib), an FDA-approved menin inhibitor for adults with relapsed or refractory (R/R) NPM1-mutated acute myeloid leukemia (AML), and darlifarnib, an investigational farnesyl transferase inhibitor.
Third-Quarter 2026 Financial Results
Kura reported net product...